GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Gross Margin %

Nutra Pharma (Nutra Pharma) Gross Margin % : 62.39% (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Nutra Pharma's Gross Profit for the three months ended in Sep. 2022 was $0.07 Mil. Nutra Pharma's Revenue for the three months ended in Sep. 2022 was $0.11 Mil. Therefore, Nutra Pharma's Gross Margin % for the quarter that ended in Sep. 2022 was 62.39%.


The historical rank and industry rank for Nutra Pharma's Gross Margin % or its related term are showing as below:


NPHC's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 47.33
* Ranked among companies with meaningful Gross Margin % only.

Nutra Pharma had a gross margin of 62.39% for the quarter that ended in Sep. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Nutra Pharma was 0.00% per year.


Nutra Pharma Gross Margin % Historical Data

The historical data trend for Nutra Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Gross Margin % Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.69 10.69 33.65 28.85 8.16

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.63 -150.00 36.36 33.33 62.39

Competitive Comparison of Nutra Pharma's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutra Pharma's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Nutra Pharma's Gross Margin % falls into.



Nutra Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Nutra Pharma's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=0 / 0.098
=(Revenue - Cost of Goods Sold) / Revenue
=(0.098 - 0.09) / 0.098
=8.16 %

Nutra Pharma's Gross Margin for the quarter that ended in Sep. 2022 is calculated as


Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=0.1 / 0.109
=(Revenue - Cost of Goods Sold) / Revenue
=(0.109 - 0.041) / 0.109
=62.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nutra Pharma  (OTCPK:NPHC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nutra Pharma had a gross margin of 62.39% for the quarter that ended in Sep. 2022 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Nutra Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutra Pharma (Nutra Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired 04-19-2018